E-DRUG: Is EMA backpedalling on its transparency policy?
---------------------------------------------------------------------------------------------------------
Dear E-Druggers
Today is International Clinical Trials Day. Unfortunately, according to documents shared by the agency during a stakeholder consultation mid-May 2014, the European Medicines Agency (EMA)’s long awaited proactive publication of clinical-data policy, to be adopted in June 2014, could undermine EU citizens’ fundamental right of public access to documents, instead of improving it.
We call on the EMA to ensure that its final proactive publication of clinical-data policy improves public access to the scientific evidence about the effects of medicines on human health, which is necessary to protect public health.
Please find below our joint press release: "Backpedalling on EMA’s “proactive publication of clinical-data” draft policy:
Was it all just a window-dressing exercise? Who or what is the EMA afraid of?"
Thank you very much for your attention. Press release is available at http://english.prescrire.org/en/
Best regards,
Association Internationale de la Mutualité (AIM)
International Society of Drug Bulletins (ISDB)
Medicines in Europe Forum (MiEF)
Nordic Cochrane Centre
Christophe KOPP <ckopp@prescrire.org>